379 related articles for article (PubMed ID: 26122097)
1. The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.
Boisgerault F; Mingozzi F
Curr Gene Ther; 2015; 15(4):381-94. PubMed ID: 26122097
[TBL] [Abstract][Full Text] [Related]
2. The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
Mays LE; Wilson JM
Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617
[TBL] [Abstract][Full Text] [Related]
3. Transduction Efficiency of Adeno-Associated Virus Serotypes After Local Injection in Mouse and Human Skeletal Muscle.
Muraine L; Bensalah M; Dhiab J; Cordova G; Arandel L; Marhic A; Chapart M; Vasseur S; Benkhelifa-Ziyyat S; Bigot A; Butler-Browne G; Mouly V; Negroni E; Trollet C
Hum Gene Ther; 2020 Feb; 31(3-4):233-240. PubMed ID: 31880951
[TBL] [Abstract][Full Text] [Related]
4. Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone.
Cramer ML; Shao G; Rodino-Klapac LR; Chicoine LG; Martin PT
Hum Gene Ther; 2017 Jun; 28(6):493-509. PubMed ID: 28345428
[TBL] [Abstract][Full Text] [Related]
5. AAV as an immunogen.
Vandenberghe LH; Wilson JM
Curr Gene Ther; 2007 Oct; 7(5):325-33. PubMed ID: 17979679
[TBL] [Abstract][Full Text] [Related]
6. Transgene regulation using the tetracycline-inducible TetR-KRAB system after AAV-mediated gene transfer in rodents and nonhuman primates.
Le Guiner C; Stieger K; Toromanoff A; Guilbaud M; Mendes-Madeira A; Devaux M; Guigand L; Cherel Y; Moullier P; Rolling F; Adjali O
PLoS One; 2014; 9(9):e102538. PubMed ID: 25248159
[TBL] [Abstract][Full Text] [Related]
7. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
[TBL] [Abstract][Full Text] [Related]
8. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.
Mueller C; Chulay JD; Trapnell BC; Humphries M; Carey B; Sandhaus RA; McElvaney NG; Messina L; Tang Q; Rouhani FN; Campbell-Thompson M; Fu AD; Yachnis A; Knop DR; Ye GJ; Brantly M; Calcedo R; Somanathan S; Richman LP; Vonderheide RH; Hulme MA; Brusko TM; Wilson JM; Flotte TR
J Clin Invest; 2013 Dec; 123(12):5310-8. PubMed ID: 24231351
[TBL] [Abstract][Full Text] [Related]
9. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.
Rivière C; Danos O; Douar AM
Gene Ther; 2006 Sep; 13(17):1300-8. PubMed ID: 16688207
[TBL] [Abstract][Full Text] [Related]
10. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
Verdera HC; Kuranda K; Mingozzi F
Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
[TBL] [Abstract][Full Text] [Related]
11. Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.
Gernoux G; Gruntman AM; Blackwood M; Zieger M; Flotte TR; Mueller C
Mol Ther; 2020 Mar; 28(3):747-757. PubMed ID: 31982038
[TBL] [Abstract][Full Text] [Related]
12. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
McIntosh JH; Cochrane M; Cobbold S; Waldmann H; Nathwani SA; Davidoff AM; Nathwani AC
Gene Ther; 2012 Jan; 19(1):78-85. PubMed ID: 21716299
[TBL] [Abstract][Full Text] [Related]
13. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678
[TBL] [Abstract][Full Text] [Related]
14. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.
Manning WC; Zhou S; Bland MP; Escobedo JA; Dwarki V
Hum Gene Ther; 1998 Mar; 9(4):477-85. PubMed ID: 9525309
[TBL] [Abstract][Full Text] [Related]
15. CpG-depleted adeno-associated virus vectors evade immune detection.
Faust SM; Bell P; Cutler BJ; Ashley SN; Zhu Y; Rabinowitz JE; Wilson JM
J Clin Invest; 2013 Jul; 123(7):2994-3001. PubMed ID: 23778142
[TBL] [Abstract][Full Text] [Related]
16. Liver induced transgene tolerance with AAV vectors.
Keeler GD; Markusic DM; Hoffman BE
Cell Immunol; 2019 Aug; 342():103728. PubMed ID: 29576315
[TBL] [Abstract][Full Text] [Related]
17. Muscle as a target for supplementary factor IX gene transfer.
Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of regulatory T cells in gene transfer.
Cao O; Furlan-Freguia C; Arruda VR; Herzog RW
Curr Gene Ther; 2007 Oct; 7(5):381-90. PubMed ID: 17979684
[TBL] [Abstract][Full Text] [Related]
19. Enhancing transduction of the liver by adeno-associated viral vectors.
Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM
Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909
[TBL] [Abstract][Full Text] [Related]
20. Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies.
Li Y; Li J; Liu Y; Shi Z; Liu H; Wei Y; Yang L
Gene Ther; 2019 Jun; 26(6):264-276. PubMed ID: 31110296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
